Global /Australia /Healthcare /Drug Manufacturers - General /BOT

Botanix Pharmaceuticals Ltd.

BOT

• ASX: BOT • Delayed

0.0280AUD -6.7%

0.0197 USD

As of 7 June 2026, Botanix Pharmaceuticals Ltd. has a market cap of $58.24M USD, ranking #29488 globally and #717 in Australia. It ranks #2672 in the Healthcare sector, and #946 in the Drug Manufacturers - General industry.

Global Rank

29488

Country Rank

717

Sector Rank

2672

Industry Rank

946

Key Stats

Market Cap

$58.24MUSD

81.61M AUD

Enterprise Value

$35.98MUSD

51.07M AUD

Revenue (TTM)

$15.64MUSD

21.92M AUD

EBITDA (TTM)

-$57.92MUSD

-82.23M AUD

Net Income (TTM)

-$63.3MUSD

-88.7M AUD

PS Ratio

3.7

PB Ratio

1.5

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Howie McKibbon open_in_new

Employees

Founded

1984

Website

botanixpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-6.7%	-9.4%	-29%	-74%	-78%	-79%	-93%	-66%	-65%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	BOT Botanix Pharmaceuticals Ltd ISIN: AU000000BOT2 Shares Out.: Shares Outstanding: 2.734B¹ Shares Float: 2.365B² TV: TradingView: ASX: BOT SA: Stock Analysis: ASX: BOT YF: Yahoo Finance: BOT.AX GF: Google Finance: ASX: BOT BA: Barron's: BOT MS: Morningstar: XASX: BOT	0.0280 AUD	TV: TradingView: ASX: BOT SA: Stock Analysis: ASX: BOT YF: Yahoo Finance: BOT.AX GF: Google Finance: ASX: BOT BA: Barron's: BOT MS: Morningstar: XASX: BOT
OTC Markets (OTCMKTS / OTC) MIC: OTCM	BXPHF Botanix Pharmaceuticals Ltd ISIN: AU000000BOT2 Shares Out.: Shares Outstanding: 1.961B¹ Shares Float: 1.364B² TV: TradingView: OTC: BXPHF SA: Stock Analysis: OTC: BXPHF YF: Yahoo Finance: BXPHF GF: Google Finance: OTCMKTS: BXPHF BA: Barron's: BXPHF MS: Morningstar: PINX: BXPHF	0.1340 USD	TV: TradingView: OTC: BXPHF SA: Stock Analysis: OTC: BXPHF YF: Yahoo Finance: BXPHF GF: Google Finance: OTCMKTS: BXPHF BA: Barron's: BXPHF MS: Morningstar: PINX: BXPHF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Botanix Pharmaceuticals Ltd.

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in West Perth, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 39K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 1K%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 495%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 476%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 272%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 186%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 940K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 619K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 557K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 497K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 476K%	20.5	Switzerland

chevron_leftBack